title: FIP1L1-PDGFRalpha in hypereosinophilic syndrome and mastocytosis.
authors.affiliation: Brigham and Women's Hospital, Boston, MA, USA.
authors.forename: Gary
authors.initials: G
authors.lastname: Gilliland
authors.forename: Jan
authors.initials: J
authors.lastname: Cools
authors.forename: Elizabeth H
authors.initials: EH
authors.lastname: Stover
authors.forename: Iwona
authors.initials: I
authors.lastname: Wlodarska
authors.forename: Peter
authors.initials: P
authors.lastname: Marynen
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D002471:Cell Transformation, Neoplastic / Q000235:genetics; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics*; D000068877:Imatinib Mesylate; D034721:Mastocytosis, Systemic / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics*; D051379:Mice; D015514:Oncogene Proteins, Fusion; D009857:Oncogenes; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D011828:Radiation Chimera; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology*; D023041:Xenograft Model Antitumor Assays; D039221:mRNA Cleavage and Polyadenylation Factors / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D004791:Enzyme Inhibitors; D015514:Oncogene Proteins, Fusion; D010879:Piperazines; D011743:Pyrimidines; D039221:mRNA Cleavage and Polyadenylation Factors; D000068877:Imatinib Mesylate; C479819:FIP1L1-PDGFRA fusion protein, human; D020796:Receptor, Platelet-Derived Growth Factor alpha